Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study

Cancer

Volumn 116, Issue 7, 2010, Pages 1725-1732

  Thomas, Xavier ^a,b   Raffoux, Emmanuel ^b   Renneville, Aline ^b,c   Pautas, Cecile ^b,d   De Botton, Stephane ^b,e   Terre, Christine ^b,f   Gardin, Claude ^b,g   Hayette, Sandrine ^a,b   Preudhomme, Claude ^b,c   Dombret, Herve ^b  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f CENTRE HOSPITALIER DE VERSAILLES   (France)

^g AVICENNE HOSPITAL   (France)

Author keywords

Acute myeloid leukemia; GM CSF; Priming; Prognosis; Timed sequential chemotherapy

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BLOOD CELL COUNT; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; REMISSION INDUCTION; RISK;

EID: 77950274995     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24943     Document Type: Article

References (34)

1. Tanaka M. Recombinant GM-CSF modulates the metabolism of cytosine arabinoside in leukemic cells in bone marrow. Leuk Res. 1993;17:585-592.
2. Te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia. 1993;7:1191-1198.
3. Reuter C, Auf der Landwehr U, Schleyer U, et al. Modulation of intracellular metabolism in cytosine arabinoside in acute myeloid leukemia by granulocyte-macrophage colony-stimulating factor. Leukemia. 1994;8:217-225.
4. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA 91 trial). Leukemia. 1999;13:1214-1220.
5. Thomas X, Raffoux E, Botton S, et al. Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia. 2007;21:453-461.
6. Castaigne S, Chevret S, Archimbaud E, et al. Randomized comparison of double induction and timed-sequential-induction to a "3 + 7" induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004;104:2467-2474.
7. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331: 896-903.
8. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92:2322-2333.
9. Preudhomme C, Sagot C, Boissel N, et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood. 2002;100:2717-2723.
10. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16:1699-1704.
11. Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile and prognosis of NPM mutations in AML with normal karyotype. Blood. 2005;106:3618-3620.
12. Poirel H, Rack K, Delabesse E, et al. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood. 1996;87:2496-2505.
13. Summers K, Stevens J, Kakkas I, et al. Wilms' tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007;21:550-551; author reply, 552.
14. Cheson BD, Cassileth PA, Head DR, et al. International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003; 21:4642-4649.
15. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349:743-752.
16. Amadori S, Suciu S, Jehn U, et al. Use of glycosylated human recombinant G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood. 2005;106:27-34.
17. Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909-1918.
18. Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22:915-931.
19. Grant SM, Neel RC. Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). Drugs. 1992;43: 516-561.
20. Carter BZ, Miella M, Altieri DC, Andreeff M. Cytokine-regulated expression of survivin in myeloid leukemia. Blood. 2001;97:2784-2790.
21. Hu JS, Freeman CM, Stolberg VR, et al. AMD3465, a novel CXCR4 receptor antagonist, abrogates Schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol. 2006;169:424-432.
22. Rombouts EJC, Pavic B, Lowenberg B, Ploemacher R. Relation between CXCR-4 expression, Flt3 mutations and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550-557.
23. Konoplev S, Rassidakis GZ, Estey E, et al. Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype. Cancer. 2007;109:1152-1156.
24. Zeng Z, Samudio IJ, Munsell M, et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther. 2006;5:3113-3121.
25. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215-6224.
26. Liesveld JL, Bechelli J, Rosell K, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007;31:1553-1563.
27. Flomenberg N, Devine SM, Dipersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106:1867-1874.
28. Andreeff M, Konoplev S, Wang RY, et al. Massive mobilization of AML cells into circulation by disruption of leukemia/ stroma cell interactions using CXCR4 antagonist AMD3100: First evidence in patients and potential for abolishing bone marrow microenvironment-mediated resistance [abstract]. Blood. 2006;108(suppl 1):171a. Abstract 568.
29. Fiegl M, Samudio I, Clise-Dwyer K, et al. CXCR4 expression and biological activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009;113:1504-1512.
30. Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia. 2005;19:1345-1349.
31. Gilliland DG. Molecular genetics of human leukemias: New insights into therapy. Semin Hematol. 2002;39:6-11.
32. Dash A, Gilliland DG. Molecular genetics of acute myeloid leukaemia. Best Pract Clin Haematol. 2001;14:49-64.
33. Libura M, Asnafi V, Tu A, et al. FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress. Blood. 2003;102:2198-2204.
34. Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3:173-183.